Altimmune/$ALT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Altimmune
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Ticker
$ALT
Sector
Primary listing
Employees
59
Headquarters
Website
Altimmune Metrics
BasicAdvanced
$435M
-
-$1.06
-0.01
-
Price and volume
Market cap
$435M
Beta
-0.01
52-week high
$9.19
52-week low
$2.90
Average daily volume
2.9M
Financial strength
Current ratio
17.183
Quick ratio
16.831
Long term debt to equity
8.436
Total debt to equity
7.783
Interest coverage (TTM)
-118.87%
Profitability
EBITDA (TTM)
-90.343
Gross margin (TTM)
-338,920.00%
Net profit margin (TTM)
-419,575.00%
Operating margin (TTM)
-452,310.00%
Effective tax rate (TTM)
0.81%
Management effectiveness
Return on assets (TTM)
-30.87%
Return on equity (TTM)
-52.61%
Valuation
Price to revenue (TTM)
16,613.546
Price to book
2.15
Price to tangible book (TTM)
2.15
Price to free cash flow (TTM)
-4.993
Free cash flow yield (TTM)
-20.03%
Free cash flow per share (TTM)
-0.835
Growth
Revenue change (TTM)
-61.54%
Earnings per share change (TTM)
-30.81%
3-year revenue growth (CAGR)
-81.80%
3-year earnings per share growth (CAGR)
-18.20%
What the Analysts think about Altimmune
Analyst ratings (Buy, Hold, Sell) for Altimmune stock.
Altimmune Financial Performance
Revenues and expenses
Altimmune Earnings Performance
Company profitability
Altimmune News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Altimmune stock?
Altimmune (ALT) has a market cap of $435M as of November 15, 2025.
What is the P/E ratio for Altimmune stock?
The price to earnings (P/E) ratio for Altimmune (ALT) stock is 0 as of November 15, 2025.
Does Altimmune stock pay dividends?
No, Altimmune (ALT) stock does not pay dividends to its shareholders as of November 15, 2025.
When is the next Altimmune dividend payment date?
Altimmune (ALT) stock does not pay dividends to its shareholders.
What is the beta indicator for Altimmune?
Altimmune (ALT) has a beta rating of -0.01. This means that it has an inverse relation to market volatility.